Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on August 25th, 2017 by Patricia MorganPharma R&D
After decades of being treated with a fairly typical combination of surgery and therapies, cancer is now being met with exciting new treatments that are more targeted and often less hard on the patient. Continue reading “Cancer Immunotherapy Webinar on September 12: Register Now” »
Posted on August 23rd, 2017 by Christine de Vries - ScheideggerPharma R&D
R&D is no longer a solely in-house process where Big Pharma researchers work diligently in secret to come up with the next blockbuster drug. Rising costs, patient needs, global trends, healthcare reform, changes in clinical development models and many other factors have altered the R&D landscape. In today’s environment, pharmaceutical firms must reach outward in order to innovate. Continue reading “Finding Key Collaborators in the Data” »
Posted on August 21st, 2017 by Neal KatzPharma R&D
High-quality compound bioactivity data and information about biological pathways and potential drug targets is more readily available than ever—and in enormous amounts that are often daunting to researchers Continue reading “Combining Data to Find New Indications, Develop New Targets & Predict Adverse Events” »
Posted on August 18th, 2017 by J.-P. Clement MDPharmacovigilance
The Policies, Procedures and other Quality Documents that we use as a backbone to our daily PV activities are the fundamental references for ensuring the consistency of the execution of our activities. They also ensure adequate documentation Continue reading “Can We Apply Leadership Skills to Writing Pharmacovigilance SOPs?” »
Posted on August 16th, 2017 by Christine de Vries - ScheideggerChemistry
R&D departments find themselves having to work with budgets that seem to get tighter all the time. One of the best ways of ensuring that investments are used on projects with the greatest probability of success Continue reading “Overcoming Commercial, Technical & Regulatory Challenges in Drug Discovery” »
Posted on August 14th, 2017 by Dr Andrew A. ParsonsPharma R&D
To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.